565 related articles for article (PubMed ID: 17652818)
1. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors.
Robert J
Cardiovasc Toxicol; 2007; 7(2):135-9. PubMed ID: 17652818
[TBL] [Abstract][Full Text] [Related]
2. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls.
Robert J
Cell Biol Toxicol; 2007 Jan; 23(1):27-37. PubMed ID: 17041747
[TBL] [Abstract][Full Text] [Related]
3. Genotyping the risk of anthracycline-induced cardiotoxicity.
Deng S; Wojnowski L
Cardiovasc Toxicol; 2007; 7(2):129-34. PubMed ID: 17652817
[TBL] [Abstract][Full Text] [Related]
4. Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials.
Bast A; Haenen GR; Bruynzeel AM; Van der Vijgh WJ
Cardiovasc Toxicol; 2007; 7(2):154-9. PubMed ID: 17652822
[TBL] [Abstract][Full Text] [Related]
5. Prevention of anthracycline-induced cardiotoxicity in children: the evidence.
van Dalen EC; Caron HN; Kremer LC
Eur J Cancer; 2007 May; 43(7):1134-40. PubMed ID: 17383867
[TBL] [Abstract][Full Text] [Related]
6. Experimental study of dexrazoxane-anthracycline combinations using the model of isolated perfused rat heart.
Plandé J; Platel D; Tariosse L; Robert J
Toxicol Lett; 2006 Feb; 161(1):37-42. PubMed ID: 16129573
[TBL] [Abstract][Full Text] [Related]
7. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
8. Anthracycline cardiotoxicity in long-term survivors of childhood cancer.
Scully RE; Lipshultz SE
Cardiovasc Toxicol; 2007; 7(2):122-8. PubMed ID: 17652816
[TBL] [Abstract][Full Text] [Related]
9. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.
Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J
Br J Pharmacol; 1996 Apr; 117(7):1593-9. PubMed ID: 8730759
[TBL] [Abstract][Full Text] [Related]
10. New iron chelators in anthracycline-induced cardiotoxicity.
Kaiserová H; Simunek T; Sterba M; den Hartog GJ; Schröterová L; Popelová O; Gersl V; Kvasnicková E; Bast A
Cardiovasc Toxicol; 2007; 7(2):145-50. PubMed ID: 17652820
[TBL] [Abstract][Full Text] [Related]
11. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
Lopez M; Vici P
Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
[TBL] [Abstract][Full Text] [Related]
12. Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries.
Langer SW; Jensen PB; Sehested M
Cardiovasc Toxicol; 2007; 7(2):151-3. PubMed ID: 17652821
[TBL] [Abstract][Full Text] [Related]
13. Ameliorating anthracycline cardiotoxicity in children with cancer: clinical trials with dexrazoxane.
Wexler LH
Semin Oncol; 1998 Aug; 25(4 Suppl 10):86-92. PubMed ID: 9768829
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
Pouillart P
Cancer Treat Rev; 2004 Nov; 30(7):643-50. PubMed ID: 15531396
[TBL] [Abstract][Full Text] [Related]
15. [Anthracyclines and the heart].
Mazzarello GP; Morra L
Recenti Prog Med; 1998 Sep; 89(9):459-64. PubMed ID: 9796378
[TBL] [Abstract][Full Text] [Related]
16. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
Jensen BV
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
[TBL] [Abstract][Full Text] [Related]
17. Role of mtDNA lesions in anthracycline cardiotoxicity.
Lebrecht D; Walker UA
Cardiovasc Toxicol; 2007; 7(2):108-13. PubMed ID: 17652814
[TBL] [Abstract][Full Text] [Related]
18. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up.
Georgakopoulos P; Roussou P; Matsakas E; Karavidas A; Anagnostopoulos N; Marinakis T; Galanopoulos A; Georgiakodis F; Zimeras S; Kyriakidis M; Ahimastos A
Am J Hematol; 2010 Nov; 85(11):894-6. PubMed ID: 20872550
[TBL] [Abstract][Full Text] [Related]
19. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism.
Cusack BJ; Gambliel H; Musser B; Hadjokas N; Shadle SE; Charlier H; Olson RD
Cancer Chemother Pharmacol; 2006 Oct; 58(4):517-26. PubMed ID: 16555089
[TBL] [Abstract][Full Text] [Related]
20. [Subacute cardiotoxicity caused by anthracycline therapy in children: can dexrazoxane prevent this effect?].
Erlaky H; Tóth K; Szabolcs J; Horváth E; Kemény V; Müller J; Csóka M; Jókúti L; Erdélyi D; Kovács G
Magy Onkol; 2006; 50(1):25-32. PubMed ID: 16617380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]